NeoGenomics Q2 EPS $(0.05) Beats $(0.11) Estimate, Sales $146.92M Beat $137.42M Estimate
Portfolio Pulse from Benzinga Newsdesk
NeoGenomics reported Q2 losses of $(0.05) per share, beating the analyst consensus estimate of $(0.11) by 54.55%. This is a 68.75% increase over losses from the same period last year. The company also reported quarterly sales of $146.92 million, beating the analyst consensus estimate of $137.42 million by 6.91%. This is a 17.47% increase over sales from the same period last year.
August 08, 2023 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeoGenomics reported better than expected Q2 results, with losses and sales both beating estimates. This could potentially lead to a positive market reaction.
NeoGenomics reported better than expected Q2 results, with both losses per share and sales beating analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100